Drug Trial Radar · NCT03767075
A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,000
Planned (sponsor's estimate)
Start
Dec 10, 2018
Primary completion
May 2027
Study completion Nov 2027
Sponsor
- Lead sponsor
- Vall d'Hebron Institute of OncologyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Roche Pharma AG; IQVIA Pty Ltd; Taisho Pharmaceutical Co., Ltd.; Janssen, LP
- First posted
- Dec 6, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The global objective of this Basket of Basket study is to evaluate the antitumor activity of each matched therapies that will be evaluated through the study in small molecularly selected populations. The objective of module 1 wil be to determine the overall response rate (ORR) at 12 weeks by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 of atezolizumab in each of the arms of the module. All patients in genomically selected populations will receive atezolizumab 1200 mg IV every 3 weeks. The objective of module 2 wil be to determine the overall response rate (ORR) at 16 weeks by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 of futibatinib in each of the arms of the module. All patients in genomically selected populations will receive will receive futibatinib, 20 mg, once daily (QD) in 28-day cycles. The objective of module 3 wil be to determine the overall response rate (ORR) at 12 weeks by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 of amivantamab in each of the arms of the module. All patients in genomically selected populations will receive amivantamab 1050 mg intravenously (IV) for body weight \< 80 kg and 1400 mg for body weight \>= 80 kg mg once weekly in Cycle 1 (with a split dose on Days 1-2) and then every 2 weeks in subsequent cycles (28-day cycles).
Conditions
- Advanced Solid Tumor
Interventions
AtezolizumabDrug
1200 mg, administered IV, once every 3 weeks
FutibatinibDrug
20 mg administered orally, once daily (QD) continuously in 28-day cycles.
AmivantamabDrug
1050 mg administered IV for body weight \< 80 kg and 1400 mg for body weight \>= 80 kg mg once weekly in Cycle 1 (with a split dose on Days 1-2) and then every 2 weeks in subsequent cycles (28-day cycles)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall response rateTime frame: From the first dose date of study treatment to first CR or PR, whichever came earlier, up to 12 weeks (Module 1 & 3) and 16 weeks (Module 2)
Locations
8 sites in 7 countries. Site status is shown where the registry gives one.
Institut Gustave Roussy
Villejuif, France · Recruiting
Universitätsklinikum Dresden
Dresden, Germany · Recruiting
Deutsches Krebsforschungszentrum (NCT/DKFZ)
Heidelberg, Baden-Wurttemberg, Germany · Recruiting
Instituto Nazionale dei Tumori di Milano
Milan, Italy · Recruiting
Nederland Kanker Instituut (NKI)
Amsterdam, Netherlands · Recruiting
Hospital Vall d'Hebron
Barcelona, Spain · Recruiting
Karolinska University Hospital Solna
Stockholm, Sweden · Recruiting
Cancer Research UK Cambridge Centre
Cambridge, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.